Comparison tool

AOD-9604 vs Semaglutide side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

AOD-9604Semaglutide

Share this peptide comparison

Property	AOD-9604	Semaglutide
Category	Weight Loss	Weight Loss
Also known as	Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191	Ozempic, Wegovy, Rybelsus
FDA approved	No	Yes
Clinical status	Clinical trials completed without FDA approval; source also reports Sept 2024 FDA Category 2 removal, expected Category 1 reclassification activity in 2026, and GRAS status. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	FDA-approved status recorded by the supplied source; it also reports several 2025-2026 indication and formulation updates. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Fat loss, body composition, localized fat reduction	Weight loss, appetite control, blood sugar management
How it works	AOD-9604 is described as a modified fragment of human growth hormone designed around the hormone's fat-metabolism region rather than the broader growth-hormone activity profile. The source reports lab and animal findings consistent with increased lipolysis and reduced lipogenesis. It also reports no meaningful IGF-1 increase, no glucose-metabolism harm in reviewed human safety evidence, and no settled receptor explanation, so the mechanism remains proposed rather than confirmed.	According to the supplied description, semaglutide stimulates the GLP-1 receptor. Reported downstream effects include increased insulin secretion when glucose is elevated, decreased glucagon, slower gastric emptying, and hypothalamic appetite signaling. A fatty-acid modification is described as promoting albumin binding and as associated with an approximately 160 hour (about 160 hours) half-life, supporting weekly administration.
Typical dosing	300 mcg daily · Once daily, usually morning fasted	1-2.4 mg weekly (after titration) · Once weekly
Research dosing	250-500 mcg daily · 12-24 weeks in studies · Subcutaneous injection or oral	0.25mg weekly (starting) · Long-term / chronic use · Subcutaneous injection weekly, or oral (Rybelsus)
Typical duration	12-24 weeks in studies	Long-term / chronic use
Administration	Subcutaneous injection or oral administration reported in studies	Subcutaneous injection weekly, or oral (Rybelsus)
Timing	Morning, fasted Empty-stomach use reported	Morning, same day each week With or without food
Evidence level	Clinical Trials	FDA Approved
Possible side effects	Generally very well-tolerated (Overall tolerability characterization reported by the source.) Injection-site reactions (Listed by the source as a reported side effect.) Mild headache (Reported as mild in the source.) +4 more Dizziness (Listed by the source as a reported side effect.) Does NOT produce typical HGH side effects (Source-reported absence of typical HGH-like effects; this does not establish individual safety.) No effect on IGF-1 levels (Source reports no IGF-1 increase in reviewed evidence.) GRAS status by expert panel (Reported safety-status item from the source rather than a symptom.)	Nausea (Common and usually transient; the source says reports vary with dose, duration, and individual health factors.) Vomiting Diarrhea +10 more Constipation Abdominal pain Headache Fatigue Injection site reactions Hypoglycemia (Source associates this report with insulin/sulfonylureas.) Gallbladder problems Pancreatitis Acute kidney injury Thyroid C-cell tumors (Boxed warning; the source lists a contraindication with MTC/MEN 2.)
Research summary	The supplied source presents a mixed evidence picture. It describes supportive cell and animal findings for fat-metabolism effects, then reports roughly six randomized, double-blind, placebo-controlled human trials involving about 900 participants. A cited safety review is summarized as finding good tolerability, no IGF-1 elevation, no glucose-metabolism harm, and no detectable antibodies. However, the source also states that the largest Phase IIb obesity trial did not beat placebo on its main weight-loss endpoint and that Metabolic Pharmaceuticals halted development around 2007.	The source characterizes the clinical literature as extensive. It reports that the SUSTAIN program established blood-sugar control in type 2 diabetes and that SUSTAIN 6 reduced cardiovascular events. For STEP 1, published in the New England Journal of Medicine in 2021, the source describes nearly 2,000 adults without diabetes in a randomized trial: at a 68 week endpoint, semaglutide 2.4 mg had 14.9 % mean weight loss versus 2.4 % with placebo, and most participants lost at least 5 %. It characterizes this as large randomized, placebo-controlled research rather than pilot data. Gastrointestinal effects, including nausea, vomiting, and constipation, were reported as most prominent during escalation; the source also reports an oral weight-management version as approved.
References	Source Source +1 more Source	Source Source +2 more Source Source
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

AOD-9604

Semaglutide

Category

Weight Loss

Also known as

Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191

Ozempic, Wegovy, Rybelsus

FDA approved

Yes

Clinical status

Clinical trials completed without FDA approval; source also reports Sept 2024 FDA Category 2 removal, expected Category 1 reclassification activity in 2026, and GRAS status.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

FDA-approved status recorded by the supplied source; it also reports several 2025-2026 indication and formulation updates.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Fat loss, body composition, localized fat reduction

Weight loss, appetite control, blood sugar management

How it works

AOD-9604 is described as a modified fragment of human growth hormone designed around the hormone's fat-metabolism region rather than the broader growth-hormone activity profile. The source reports lab and animal findings consistent with increased lipolysis and reduced lipogenesis. It also reports no meaningful IGF-1 increase, no glucose-metabolism harm in reviewed human safety evidence, and no settled receptor explanation, so the mechanism remains proposed rather than confirmed.

According to the supplied description, semaglutide stimulates the GLP-1 receptor. Reported downstream effects include increased insulin secretion when glucose is elevated, decreased glucagon, slower gastric emptying, and hypothalamic appetite signaling. A fatty-acid modification is described as promoting albumin binding and as associated with an approximately 160 hour (about 160 hours) half-life, supporting weekly administration.

Typical dosing

300 mcg daily · Once daily, usually morning fasted

1-2.4 mg weekly (after titration) · Once weekly

Research dosing

250-500 mcg daily · 12-24 weeks in studies · Subcutaneous injection or oral

0.25mg weekly (starting) · Long-term / chronic use · Subcutaneous injection weekly, or oral (Rybelsus)

Typical duration

12-24 weeks in studies

Long-term / chronic use

Administration

Subcutaneous injection or oral administration reported in studies

Subcutaneous injection weekly, or oral (Rybelsus)

Timing

Morning, fasted

Empty-stomach use reported

Morning, same day each week

With or without food

Evidence level

Clinical Trials

FDA Approved

Possible side effects

Generally very well-tolerated (Overall tolerability characterization reported by the source.)
Injection-site reactions (Listed by the source as a reported side effect.)
Mild headache (Reported as mild in the source.)

+4 more

Dizziness (Listed by the source as a reported side effect.)
Does NOT produce typical HGH side effects (Source-reported absence of typical HGH-like effects; this does not establish individual safety.)
No effect on IGF-1 levels (Source reports no IGF-1 increase in reviewed evidence.)
GRAS status by expert panel (Reported safety-status item from the source rather than a symptom.)

Nausea (Common and usually transient; the source says reports vary with dose, duration, and individual health factors.)
Vomiting
Diarrhea

+10 more

Constipation
Abdominal pain
Headache
Fatigue
Injection site reactions
Hypoglycemia (Source associates this report with insulin/sulfonylureas.)
Gallbladder problems
Pancreatitis
Acute kidney injury
Thyroid C-cell tumors (Boxed warning; the source lists a contraindication with MTC/MEN 2.)

Research summary

The supplied source presents a mixed evidence picture. It describes supportive cell and animal findings for fat-metabolism effects, then reports roughly six randomized, double-blind, placebo-controlled human trials involving about 900 participants. A cited safety review is summarized as finding good tolerability, no IGF-1 elevation, no glucose-metabolism harm, and no detectable antibodies. However, the source also states that the largest Phase IIb obesity trial did not beat placebo on its main weight-loss endpoint and that Metabolic Pharmaceuticals halted development around 2007.

The source characterizes the clinical literature as extensive. It reports that the SUSTAIN program established blood-sugar control in type 2 diabetes and that SUSTAIN 6 reduced cardiovascular events. For STEP 1, published in the New England Journal of Medicine in 2021, the source describes nearly 2,000 adults without diabetes in a randomized trial: at a 68 week endpoint, semaglutide 2.4 mg had 14.9 % mean weight loss versus 2.4 % with placebo, and most participants lost at least 5 %. It characterizes this as large randomized, placebo-controlled research rather than pilot data. Gastrointestinal effects, including nausea, vomiting, and constipation, were reported as most prominent during escalation; the source also reports an oral weight-management version as approved.

References

+1 more

+2 more

Full profile